D. Talbot

D. Talbot, A. Vincent, J. Newsom-Davis, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Immunotargets and Therapy the Association between Lambert–eaton Myasthenic Syndrome and Small Cell Lung Carcinoma Historical Context Pathophysiology of Lems

D. Talbot, S. Briggs, P. Gozzard, 2022 .

A phase II study of bryostatin 1 in metastatic malignant melanoma.

A. Harris, K. O'Byrne, T. Ganesan, 1998, British Journal of Cancer.

Survivin in Solid Tumors: Rationale for Development of Inhibitors

D. Talbot, D. Church, 2012, Current Oncology Reports.

Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines

H. Burger, D. Talbot, D. Talbot, 2002, British Journal of Cancer.

DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter Trial

P. Ellis, D. Dunlop, M. Ranson, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Effects of thymidine (tdr) and/or purines on the reversibility of methotrexate (mtx) toxicity in mice. Abstr.

D. Talbot, K. Harrap, J. Straw, 1976 .

Low-Dose IFN-γ Induces Tumor MHC Expression in Metastatic Malignant Melanoma

A. Harris, T. Ganesan, J. Braybrooke, 2003 .

Some observations on the reversibility of methotrexate toxicity in normal proliferating tissues.

D. Talbot, K. Harrap, J. Straw, 1977, Journal of the National Cancer Institute.

Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer.

K. O'Byrne, D. Talbot, A. Giatromanolaki, 1997, British Journal of Cancer.

First human dose study evaluating safety and pharmacokinetics of LY2181308, an antisense oligonucleotide designed to inhibit survivin

M. Ranson, J. Bono, D. Talbot, 2008 .

A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia.

S. Joel, D. Talbot, M. Slevin, 1993, British Journal of Cancer.

Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression.

A. Harris, J. Braybrooke, S. Joel, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Targeted Next-Generation Sequencing of Plasma DNA from Cancer Patients: Factors Influencing Consistency with Tumour DNA and Prospective Investigation of Its Utility for Diagnosis

N. Popitsch, G. Wilson, Jenny C. Taylor, 2016, PloS one.

Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment

Nick A Maskell, S. Tsim, K. Blyth, 2016, European Respiratory Review.

Diagnostic and Management Pathways for Pulmonary Carcinoid Tumours in the United Kingdom: Results from the National Lung Neuroendocrine Tumour Pathway Project

D. Talbot, S. Ferguson, W. Mansoor, 2020, International journal of endocrinology.

Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study

M. Ranson, P. Price, J. Matthews, 2010, Clinical Cancer Research.

Quantitative Analysis of Survivin Protein Expression and Its Therapeutic Depletion by an Antisense Oligonucleotide in Human Lung Tumors

P. McHugh, D. Talbot, David Breen, 2012, Molecular therapy. Nucleic acids.

Radiologic characteristics and management of screen-detected metastatic carcinoid tumor of the breast: a case report.

D. Talbot, C. Hughes, R. F. Adams, 2009, Clinical breast cancer.

Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

Keunchil Park, M. Krzakowski, S. Ramalingam, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survivin-directed Anticancer Therapies - A Review of Pre-clinical Data and Early-phase Clinical Trials Current Issues Novel Therapies

Denis C. Talbot, D. Talbot, H. Doolittle, 2010 .

Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: toxicity, hormonal, and immunological effects.

M. Dowsett, A. Harris, K. O'Byrne, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Teicoplanin compared to flucloxacillin for antibiotic treatment of neutropenic patients

M. Gore, D. Talbot, R. Powles, 1990, British journal of haematology.

PROGNOSTIC VALUE OF ANGIOGENESIS IN OPERABLE NON‐SMALL CELL LUNG CANCER

A. Harris, D. Talbot, K. Gatter, 1996, The Journal of pathology.

Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions.

A. Harris, F. Gleeson, K. O'Byrne, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

The systemic treatment of non-small-cell lung cancer.

D. Talbot, D. Propper, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer.

M. Ranson, J. Braybrooke, D. Talbot, 2003, Lung cancer.

Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin.

T. Hickish, M. Nicolson, D. Talbot, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A pilot study of mitomycin, cisplatin and continuous infusion 5-fluorouracil (MCF) in advanced non-small-cell lung cancer.

P. Ellis, M. Nicolson, D. Talbot, 1995, British Journal of Cancer.

Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer.

P. Ellis, M. Nicolson, D. Talbot, 1995, British Journal of Cancer.

ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)

R. Govindan, G. Fasola, P. Postmus, 2018, Cancer.

Cyclosporine-induced graft-versus-host disease following autologous bone marrow transplantation in acute myeloid leukaemia.

D. Talbot, R. Powles, J. Sloane, 1990, Bone marrow transplantation.

Ocular Toxicity of Mitogen-Activated Protein Kinase Inhibitors

D. Talbot, S. Downes, Robert M. J. Purbrick, 2017, JAMA oncology.

The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients.

D. Fabbro, A. Harris, F. Caponigro, 1999, Cancer research.

Isolation of a small molecule inhibitor of DNA base excision repair

M. Sternberg, P. Freemont, G. Dianov, 2005, Nucleic acids research.

Potential role of bcl‐2 as a suppressor of tumour angiogenesis in non‐small‐cell lung cancer

A. Harris, K. O'Byrne, D. Talbot, 1997, International journal of cancer.

What is the extent of the advantage of video-assisted thoracoscopic surgical resection over thoracotomy in terms of delivery of adjuvant chemotherapy following non-small-cell lung cancer resection?

D. Talbot, D. Church, E. Belcher, 2014, Interactive cardiovascular and thoracic surgery.

Signet-ring cell lymphoma of bone marrow.

K. Maclennan, D. Talbot, I. Smith, 1994, Journal of clinical pathology.

New perspectives in lung cancer.5. New drugs in lung cancer.

D. Talbot, I. Smith, 1992, Thorax.

Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.

A. Harris, T. Ganesan, J. Braybrooke, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.

A. Harris, J. Foekens, J. Wood, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

A pilot study of increasing dose intensity of epirubicin and ifosfamide in patients with small cell lung cancer by using recombinant granulocyte colony-stimulating factor.

A. Harris, D. Rea, P. Philip, 1999, Clinical oncology (Royal College of Radiologists (Great Britain)).

Advances in Brief Thymidine Phosphorylase Moderates Thymidine-dependent Rescue after Exposure to the Thymidylate Synthase Inhibitor ZD 1694 ( Tomudex ) in Vitro

D. Talbot, I. Stratford, Adrián, 2006 .

Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma

A. Harris, T. Ganesan, P. H. Jones, 2004, British Journal of Cancer.

Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).

J. V. van Meerbeeck, A. Price, P. Baas, 2013, European journal of cancer.

A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.

A. Harris, K. O'Byrne, T. Ganesan, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Phase II Study of Razoxane , an Antiangiogenic Topoisomerase II Inhibitor , in Renal Cell Cancer with Assessment of Potential Surrogate Markers of Angiogenesis 1

A. Harris, K. O'Byrne, T. Ganesan, 2000 .

A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor α Inhibitor in Patients with Metastatic Breast Cancer

A. Harris, T. Ganesan, J. Braybrooke, 2004, Clinical Cancer Research.

Protection against Omicron BA.2 reinfection conferred by primary Omicron or pre-Omicron infection with and without mRNA vaccination

D. Skowronski, M. Brisson, D. Talbot, 2022 .

Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study

D. Skowronski, P. De Wals, M. Brisson, 2022, The Lancet Infectious Diseases.

The development of a structured rating schedule (the BAS) to assess skills in breaking bad news

D. Talbot, T. Hope, S. Miller, 1999, British Journal of Cancer.

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

N. Tunariu, W. Brugger, D. Talbot, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients with Non–Small-Cell Lung Cancer: A Randomized Open-Label Phase II Study

G. Bepler, R. Ramlau, D. Talbot, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

In Reply: Response to Marioni

D. Talbot, D. Church, 2013, Current Oncology Reports.

Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients

M. Ranson, P. Price, J. Matthews, 2011, Theranostics.

Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma.

D. Talbot, C. Winearls, I. Roberts, 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

A randomised, concentration-controlled, comparison of standard (5-day) vs. prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancer.

K. O'Byrne, S. Joel, D. Talbot, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma

D. Talbot, Armand Morel, 2010 .

Phase II study of liarozole in advanced non-small cell lung cancer.

A. Harris, K. O'Byrne, D. Lane, 1998, European journal of cancer.